Kalcifediol Faes

Calcifediol Monohydrate, the active ingredient in Kalcifediol Faes, is a vitamin D analog presented as an oral dosage form for oral use. It is used to correct vitamin D deficiency, manage secondary hyperparathyroidism, and support bone health in adults and children.

GNH USA supplies Kalcifediol Faes as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Its network covers major markets across Europe, Asia and the Americas, ensuring timely access to essential vitamin D therapy.

Calcifediol is indicated for conditions related to vitamin D metabolism and bone health.

- Vitamin D deficiency: restores adequate serum 25‑hydroxyvitamin D levels to support calcium absorption. - Secondary hyperparathyroidism: reduces elevated parathyroid hormone concentrations associated with chronic kidney disease. - Bone health maintenance: contributes to normal bone remodeling and mineralization in adults at risk of osteopenia.

Calcifediol may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Hypercalcemia: elevated blood calcium levels causing fatigue or nausea. - Hyperphosphatemia: increased serum phosphate, occasionally leading to muscle cramps. - Gastrointestinal discomfort: mild abdominal pain, constipation or diarrhea. - Headache: transient mild headache episodes.

Serious or Rare Side Effects: - Nephrolithiasis: kidney stone formation due to calcium precipitation. - Hypercalciuria: excessive urinary calcium excretion, potentially damaging kidneys. - Allergic reactions: rash, pruritus or angioedema in sensitive individuals. - Severe hypercalcemia: confusion, arrhythmia or cardiac arrest in extreme cases.

When using Calcifediol, certain precautions should be observed to minimize risk and ensure optimal therapy.

- Assess baseline: measure serum calcium, phosphate and 25‑hydroxyvitamin D before initiating therapy. - Monitor levels: repeat laboratory tests periodically to detect hypercalcemia or hyperphosphatemia. - Renal impairment: adjust use in patients with severe kidney disease due to altered conversion to active form. - Drug interactions: review concomitant medications that affect calcium metabolism. - Pregnancy and lactation: use only if clearly needed and prescribed by a healthcare professional. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Calcifediol can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Thiazide diuretics: may increase risk of hypercalcemia. - Calcium supplements: can exacerbate hypercalcemia when combined. - Vitamin D analogues (e.g., calcitriol): additive effect on calcium levels.

Moderate Interactions (Monitor Closely): - Anticonvulsants (phenytoin, phenobarbital): may enhance metabolism and lower vitamin D levels. - Glucocorticoids: can reduce calcium absorption and counteract benefits. - Bisphosphonates: concurrent use may require monitoring of bone turnover markers.